07-28-04

EXPRESS MAIL NO.: EV475140807US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Jerome B. Zeldis

Confirmation No.: 2389

Application No:

10/693,722

Group Art Unit: 1614

Filed:

October 23, 2003

Examiner: To Be Assigned

Jones Day Docket No.: 9516-078-999

For: METHODS OF USING AND

COMPOSITIONS COMPRISING

SELECTIVE CYTOKINE INHIBITORY

DRUGS FOR TREATMENT,

MODIFICATION AND MANAGEMENT

OF PAIN

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicants hereby direct the Examiner's attention to the references A01-A119 listed on the attached form PTO 1449 entitled "List of References Cited by Applicant."

Identification of the listed references is not to be construed an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application. Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing of the first Office action on the merits. Therefore, no fee is believed to be due.

Should any fee be required, however, please charge such fee to Jones Day Deposit Account No. 503013.

Respectfully submitted,

Date July 26, 2004

52,042

For: Anthony M. Insogna

35,203

JONES DAY 222 East 41st Street

New York, New York 10017

(212) 790-9090

Enclosures

APPLICATION NO.

9516-078-999 (CAM: 501872-999077)

ATTY DOCKET NO.

10/693,722

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)



Zeldis

APPLICANT

FILING DATE 10-23-03

GROUP 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATI
MILIAL	A01	09/781,179	02-12-01	Muller	CLASS	JOBOLASS	ALTROPRIAT
	A02	09/972,487	10-05-01	Robarge			
	A03	10/032,286	12-21-01	Robarge		-	<u> </u>
	A04	10/105,833	03-25-02	Muller			
	A05	10/243,927	09-13-02	Muller			*
	A06	10/316,673	12-11-02	Muller et al.			
	A07	60/436,975	12-30-02	Muller et al.			<u> </u>
	A08	60/438,448	01-07-03	G. Muller et al.			-
	A09	60/438,450	01-07-03	Muller et al.			
	A10	60/452,460	03-05-03	G. Muller et al.			
	A11	60/454,149	03-12-03	Muller et al.			
	A12	60/454,149	03-12-03	Man et al			
	A13	60/454,155	03-12-03	Muller et al.			
	A14	10/392,195	03-19-03	Muller et al.	-		
··· =	A15	10/462,319	06-16-03	Muller et al.			
	A16	10/622,618	07-17-03	Muller et al.			
	A17	60/499,723	09-04-03	Jaworsky			
	A18	10/685,942	10-14-03	Man et al.			
	A19	10/715,184	11-17-03	Muller et al.			
	A20	10/748,085	12-29-03	Man et al.	·		
	A21	10/786,822	02-25-04	Man et al.		-	
	A22	10/794,931	03-05-04	Muller et al.		 -	
	A23	10/798,372	03-12-04	Man et al.			
	A24	2002/0045643	04-18-02	Muller et al.			
	A25	2003/0045552	03-06-03	Robarge et al.			
	A26	2003/0096841	05-22-03	Robarge et al.			

A27 2004/0038874 A1 02-26-04 Omoigui A28 3,536,809 10-27-70 Applezweig A29 3,598,123 08-10-71 Zaffaroni A30 3,845,770 11-05-74 Theeuwes et al. A31 3,916,899 11-04-75 Theeuwes et al. A32 4,008,719 02-22-77 Theeuwes et al. A33 5,059,595 10-22-91 La Grazie A34 5,073,543 12-17-91 Marshall et al. A35 5,120,548 06-09-92 McClelland et al. A36 5,134,127 07-28-92 Stella et al. A37 5,354,556 10-11-94 Sparks et al. A38 5,463,063 10-31-95 Muller A39 5,591,767 01-07-97 Mohr et al. A40 5,593,990 01-14-97 D'Amato A41 5,605,914 02-25-97 Muller A42 5,639,377 05-13-97 D'Amato A43 5,639,476 06-07-97 Muller et al. A45 5,658,940 08-19-97 Mu	- `.
A29 3,598,123 08-10-71 Zaffaroni A30 3,845,770 11-05-74 Theeuwes et al. A31 3,916,899 11-04-75 Theeuwes et al. A32 4,008,719 02-22-77 Theeuwes et al. A33 5,059,595 10-22-91 La Grazie A34 5,073,543 12-17-91 Marshall et al. A35 5,120,548 06-09-92 McClelland et al. A36 5,134,127 07-28-92 Stella et al. A37 5,354,556 10-11-94 Sparks et al. A38 5,463,063 10-31-95 Muller A39 5,591,767 01-07-97 Mohr et al. A40 5,593,990 01-14-97 D'Amato A41 5,605,914 02-25-97 Muller A42 5,629,327 05-13-97 D'Amato A43 5,635,517 06-03-97 Muller et al. A44 5,639,476 06-07-97 Oshlack et al.	
A30 3,845,770 11-05-74 Theeuwes et al. A31 3,916,899 11-04-75 Theeuwes et al. A32 4,008,719 02-22-77 Theeuwes et al. A33 5,059,595 10-22-91 La Grazie A34 5,073,543 12-17-91 Marshall et al. A35 5,120,548 06-09-92 McClelland et al. A36 5,134,127 07-28-92 Stella et al. A37 5,354,556 10-11-94 Sparks et al. A38 5,463,063 10-31-95 Muller A39 5,591,767 01-07-97 Mohr et al. A40 5,593,990 01-14-97 D'Amato A41 5,605,914 02-25-97 Muller A42 5,629,327 05-13-97 D'Amato A43 5,635,517 06-03-97 Muller et al. A44 5,639,476 06-17-97 Oshlack et al.	
A31 3,916,899 11-04-75 Theeuwes et al. A32 4,008,719 02-22-77 Theeuwes et al. A33 5,059,595 10-22-91 La Grazie A34 5,073,543 12-17-91 Marshall et al. A35 5,120,548 06-09-92 McClelland et al. A36 5,134,127 07-28-92 Stella et al. A37 5,354,556 10-11-94 Sparks et al. A38 5,463,063 10-31-95 Muller A39 5,591,767 01-07-97 Mohr et al. A40 5,593,990 01-14-97 D'Amato A41 5,605,914 02-25-97 Muller A42 5,629,327 05-13-97 D'Amato A43 5,635,517 06-03-97 Muller et al. A44 5,639,476 06-17-97 Oshlack et al.	
A32 4,008,719 02-22-77 Theeuwes et al. A33 5,059,595 10-22-91 La Grazie A34 5,073,543 12-17-91 Marshall et al. A35 5,120,548 06-09-92 McClelland et al. A36 5,134,127 07-28-92 Stella et al. A37 5,354,556 10-11-94 Sparks et al. A38 5,463,063 10-31-95 Muller A39 5,591,767 01-07-97 Mohr et al. A40 5,593,990 01-14-97 D'Amato A41 5,605,914 02-25-97 Muller A42 5,629,327 05-13-97 D'Amato A43 5,635,517 06-03-97 Muller et al. A44 5,639,476 06-17-97 Oshlack et al.	
A33 5,059,595 10-22-91 La Grazie	
A34 5,073,543 12-17-91 Marshall et al. A35 5,120,548 06-09-92 McClelland et al. A36 5,134,127 07-28-92 Stella et al. A37 5,354,556 10-11-94 Sparks et al. A38 5,463,063 10-31-95 Muller A39 5,591,767 01-07-97 Mohr et al. A40 5,593,990 01-14-97 D'Amato A41 5,605,914 02-25-97 Muller A42 5,629,327 05-13-97 D'Amato A43 5,635,517 06-03-97 Muller et al. A44 5,639,476 06-17-97 Oshlack et al.	
A34 5,073,343 12-17-91 Matshall et al. A35 5,120,548 06-09-92 McClelland et al. A36 5,134,127 07-28-92 Stella et al. A37 5,354,556 10-11-94 Sparks et al. A38 5,463,063 10-31-95 Muller A39 5,591,767 01-07-97 Mohr et al. A40 5,593,990 01-14-97 D'Amato A41 5,605,914 02-25-97 Muller A42 5,629,327 05-13-97 D'Amato A43 5,635,517 06-03-97 Muller et al. A44 5,639,476 06-17-97 Oshlack et al.	
A36 5,134,127 07-28-92 Stella et al. A37 5,354,556 10-11-94 Sparks et al. A38 5,463,063 10-31-95 Muller A39 5,591,767 01-07-97 Mohr et al. A40 5,593,990 01-14-97 D'Amato A41 5,605,914 02-25-97 Muller A42 5,629,327 05-13-97 D'Amato A43 5,635,517 06-03-97 Muller et al. A44 5,639,476 06-17-97 Oshlack et al.	
A37 5,354,556 10-11-94 Sparks et al. A38 5,463,063 10-31-95 Muller A39 5,591,767 01-07-97 Mohr et al. A40 5,593,990 01-14-97 D'Amato A41 5,605,914 02-25-97 Muller A42 5,629,327 05-13-97 D'Amato A43 5,635,517 06-03-97 Muller et al. A44 5,639,476 06-17-97 Oshlack et al.	<u> </u>
A38 5,463,063 10-31-95 Muller A39 5,591,767 01-07-97 Mohr et al. A40 5,593,990 01-14-97 D'Amato A41 5,605,914 02-25-97 Muller A42 5,629,327 05-13-97 D'Amato A43 5,635,517 06-03-97 Muller et al. A44 5,639,476 06-17-97 Oshlack et al.	
A39 5,591,767 01-07-97 Mohr et al. A40 5,593,990 01-14-97 D'Amato A41 5,605,914 02-25-97 Muller A42 5,629,327 05-13-97 D'Amato A43 5,635,517 06-03-97 Muller et al. A44 5,639,476 06-17-97 Oshlack et al.	
A40 5,593,990 01-14-97 D'Amato A41 5,605,914 02-25-97 Muller A42 5,629,327 05-13-97 D'Amato A43 5,635,517 06-03-97 Muller et al. A44 5,639,476 06-17-97 Oshlack et al.	
A41 5,605,914 02-25-97 Muller A42 5,629,327 05-13-97 D'Amato A43 5,635,517 06-03-97 Muller et al. A44 5,639,476 06-17-97 Oshlack et al.	
A42 5,629,327 05-13-97 D'Amato A43 5,635,517 06-03-97 Muller et al. A44 5,639,476 06-17-97 Oshlack et al.	
A43 5,635,517 06-03-97 Muller et al. A44 5,639,476 06-17-97 Oshlack et al.	
A44 5,639,476 06-17-97 Oshlack et al.	
A45 5 658 940 08-19-97 Muller et al	
A43 3,036,940 00-19-97 Number et al.	
A46 5,674,533 10-07-97 Santus et al.	
A47 5,698,579 12-16-97 Muller	
A48 5,703,092 12-30-97 Xue, et al.,	
A49 5,703,098 12-30-97 Muller	
A50 5,728,844 03-17-98 Muller	
A51 5,728,845 03-17-98 Muller	
A52 5,733,566 03-31-98 Lewis	
A53 5,736,570 04-07-98 Muller	
A54 5,798,368 08-25-98 Muller et al.	
A55 5,801,195 09-01-98 Muller et al.	
A56 5,874,448 02-23-99 Muller et al.	
A57 5,877,200 03-02-99 Muller	
A58 5,929,117 07-27-99 Muller et al.	
A59 5,955,476 09-21-99 Muller et al.	
A60 5,968,945 10-19-99 Muller et al.	
A61 6,011,050 01-04-00 Muller et al.	
A62 6,020,358 01-04-00 Muller et al.	

	A63	6,046,221	04-04-00	Muller et al.
	A64	6,071,948	06-06-00	D'Amato
	A65	6,075,041	06-13-00	Muller et al.
	A66	6,130,226	10-10-00	Muller et al.
	A67	6,180,644	01-30-01	Muller et al.
	A68	6,200,987	03-13-01	Muller
	A69	6,214,857	04-10-01	Muller et al.
	A70	6,262,101	07-17-01	Muller et al.
	A71	6,281,230	08-28-01	Muller et al.
	A72	6,284,780	09-04-01	Muller et al.
	A73	6,316,471	11-13-01	Muller et al.
	A74	6,326,388	12-04-01	Man et al.
	A75	6,335,349	01-01-02	Muller et al.
	A76	6,380,239	04-30-02	Muller et al.
	A77	6,395,754	05-28-02	Muller et al.
	A78	6,403,613	06-11-02	Man et al.
	A79	6,429,221	08-06-02	Muller et al
-	A80	6,458,810	10-01-02	Muller et al.
	A81	6,476,052	11-05-02	Muller et al.
	A82	6,479,554	11-12-02	Muller et al.
	A83	6,518,281	02-11-03	Muller et al.
-	A84	6,555,554	04-29-03	Muller et al.
	A85	6,635,250	10-21-03	Olmarker et al.
	A86	6,656,964	12-02-03	Muller et al.
	A87	6,667,316	12-23-04	Man et al.
	A88	6,699,899	03-02-04	Man et al.

		FOREIG	N PATENT DOCUMENTS				
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
						YES	NO
A89	WO 03/080048	10-02-03	PCT				
 A90	WO 03/080049	03-20-03	PCT				
A91	WO 00/18409	04-06-00	PCT				
A92	WO 01/34606	05-17-01	PCT				
A93	WO 01/45702	06-28-01	PCT				<u> </u>
A94	WO 02/059106	08-01-02	PCT				
A95	WO 95/01348	01-12-95	PCT				

A96	WO 97/08143	03-06-97	PCT	
 A97	WO 97/23457	07-03-97	PCT	
A98	WO 98/03502	01-29-98	PCT	
A99	WO 98/54170	12-03-98	PCT	
 A100	WO 99/06041	02-11-99	PCT	

	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
A101	Abbott, F. et al. Pain 60:91-102 (1995)
A102	Arruda, Janice L. et al., Brain Research, 879, 216-225, 2000
A103	Bennett G J, Clinical journal of pain, 16(3 Suppl) S139-143, 2000
A104	Toussirot E., et al., Expert opinion on investigational drugs, 10(1), 21-9, Jan. 2001
A105	Carstensen, Jens T., Drug Stability: Principles & Practice, 2d. Ed., Marcel Dekker, NY, NY, 1995, pp. 379-80
A106	Corral, L.G. et al., Ann. Rheum. Dis. 58:(Suppl I) 1107-1113 (1999)
A107	Dray, A., British Journal of Anaesthesia, 75: 125-131, 1995
A108	Dzwierzynski et al., Hand Clinics Vol 10 (1): 29-44 (1994
A109	Feng Huang, et al., Arthritis and rheumatism, 47(3), 249-54, Jun. 2002
A110	George, et al., Pain, 88, 267-275, 2000
A111	Hogan, Q., Regional Anesthesia and Pain Medicine 27(4):385-401 (2002)
A112	Langerman et al., Pharmacol. Toxicol. Methods 34:23-27 (1995)
A113	Malmberg, A. and Yaksh, T., Pain 60:83-90 (1995)
A114	Miller, J.M., et al., Antibiot. Med. Clin. Ther., 7, 743-746, 1960
A115	Perez R.S., et al., J Pain Symptom Manage 2001 Jun; 21(6): 511-26
A116	Rajkumar, S.V., et al., Archives of internal medicine, 161, 2502-3, Nov. 2001
A117	Schwartzman R.J., N Engl J Med 343(9): 654 (2000)
A118	Schwartzman R.J., Curr Opin Neurol Neurosurg 6(4): 531-6 (1993)
A119	1 Burger's Medicinal Chemistry and Drug Discovery, 172-178, 949-982 (Manfred E. Wolff ed., 5th ed. 1995)

	EXAMINER	DATE CONSIDERED
--	----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.